Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance

Linda Chi Hang Chu, Chiara Pozzessere, Celia Corona Villalobos, Sandra Castaños, Neda Rastegar, Vivek Halappa, Susanne Bonekamp, Emi Emurano, Ihab R Kamel

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.

Original languageEnglish (US)
JournalJournal of Computer Assisted Tomography
DOIs
StateAccepted/In press - Sep 27 2016

Fingerprint

Hepatocellular Carcinoma
Magnetic Resonance Spectroscopy
Liver
Neoplasms
Students

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance. / Chu, Linda Chi Hang; Pozzessere, Chiara; Corona Villalobos, Celia; Castaños, Sandra; Rastegar, Neda; Halappa, Vivek; Bonekamp, Susanne; Emurano, Emi; Kamel, Ihab R.

In: Journal of Computer Assisted Tomography, 27.09.2016.

Research output: Contribution to journalArticle

@article{725f43a413674d6b9ac214abb8cd026f,
title = "Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance",
abstract = "OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.",
author = "Chu, {Linda Chi Hang} and Chiara Pozzessere and {Corona Villalobos}, Celia and Sandra Casta{\~n}os and Neda Rastegar and Vivek Halappa and Susanne Bonekamp and Emi Emurano and Kamel, {Ihab R}",
year = "2016",
month = "9",
day = "27",
doi = "10.1097/RCT.0000000000000457",
language = "English (US)",
journal = "Journal of Computer Assisted Tomography",
issn = "0363-8715",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance

AU - Chu, Linda Chi Hang

AU - Pozzessere, Chiara

AU - Corona Villalobos, Celia

AU - Castaños, Sandra

AU - Rastegar, Neda

AU - Halappa, Vivek

AU - Bonekamp, Susanne

AU - Emurano, Emi

AU - Kamel, Ihab R

PY - 2016/9/27

Y1 - 2016/9/27

N2 - OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.

AB - OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.

UR - http://www.scopus.com/inward/record.url?scp=84988924620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988924620&partnerID=8YFLogxK

U2 - 10.1097/RCT.0000000000000457

DO - 10.1097/RCT.0000000000000457

M3 - Article

C2 - 27680411

AN - SCOPUS:84988924620

JO - Journal of Computer Assisted Tomography

JF - Journal of Computer Assisted Tomography

SN - 0363-8715

ER -